The market is displaying a mixed sentiment towards
Pfizer stocks. Despite lowering forecast values, cutting price targets, and discontinuing research into a prominent
obesity drug, investors still deem Pfizer as a strong
value investment for its safe yields. Potential challenges include the investigation into vaccine timing and the failed weight-loss pill. Analysts express concerns, noting a downward trend in earnings and investor returns. Yet, the stock’s
high dividend yield and its status as one of the “best very cheap stocks to buy right now” continue drawing investor interest. The discontinuation of the obesity drug Danuglipron does not impact the company's valuation, and their established drug pipeline offers potential for a rescue in share prices. Predicted to perform well in the future, Pfizer could emerge as a top player by 2030, surpassing other biotech corporations. Nonetheless, the stock remains volatile, with a recorded 52-week low in the midst of market shifts, implying investors should tread with caution.
Pfizer Stocks News Analytics from Tue, 17 Dec 2024 08:00:00 GMT to Sat, 26 Apr 2025 15:09:15 GMT -
Rating -2
- Innovation 0
- Information 6
- Rumor 1
